ESCRS 2023: New artificial intelligence integrations are ahead for iCare

News
Video

The diagnostics company is using AI to screen for diabetic retinopathy, glaucoma and age-related macular degeneration

Artificial intelligence (AI) was a popular topic at this year’s European Society of Cataract and Refractive Surgeons (ESCRS) meeting. At the meeting, our team stopped by the iCare booth to see how AI is improving diagnostic speed and accuracy, for patients of all ages.


Editor's note: The below transcript has been lightly edited for clarity.

Kasperi Kankare: I'm Kasperi Kankare. I'm a key account manager at iCare Finland.

iCare has brought to the ESCRS this year 3 fantastic and unique solutions. We brought something new to glaucoma, we have brought the new iCare IC200, which is faster than ever and with its new quick measurement mode, it also enables measuring paediatric patients, from infants to the grownups, in a 200-degree angle, a complete freedom. Also we have iCare home, which enables the patient to do a home tonometry, which then can deliver the true intraocular pressure value to ophthalmologists and caregivers. And most importantly for glaucoma, we have now brought the new COMPASS. It delivers [an] absolutely fantastic visual field examination within just 4 minutes without [a] trial lens. I would enable the combined COMPASS with the iCare home. Because how you can treat glaucoma without knowing the true intraocular pressure of the patient?

On retina, iCare has always been leading a retina camera manufacturer. Our proprietary true color technology delivers a clear, high contrast image. The iCare ILLUME is the perfect marriage of our DRSplus fully-automatic retinal imaging solution, combined with a cloud service and artificial intelligence, which enables a caregiver to do a patient screening for 3 pathologies: diabetic retinopathy, AMD and glaucoma. Within a time period of 3 minutes from the imaging to the AI report. We have a lot of new interesting things upcoming. What I personally am awaiting most is to work with the artificial intelligence in ILLUME, because that is truly game-changing in our field.


Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.